News2020-12-05T08:54:57-05:00
Page-TitleNEWS

Virpax Enters into License Agreement to Develop High-Density Molecular Masking Spray Formulation (MMS019) for the Prevention of Respiratory Viruses

Nasal Powder Spray May Provide Barrier for Cell Transmission of Respiratory Infections Virpax Pharmaceuticals Inc. (“Virpax”), today announced the signing of a technology license agreement with Nanomerics Ltd. (“Nanomerics”) for the exclusive North America rights to use Nanomerics’ High-Density Molecular Masking Spray (MMS019) for the prevention of seasonal influenza [...]

August 24th, 2020|Press Release|

Virpax Pharmaceuticals Announces Appointment of Christopher M. Chipman, Chief Financial Officer

Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products that incorporate the use of novel drug delivery systems for pain management, today announced the appointment of Christopher M. Chipman, CPA, Chief Financial Officer. “As Chairman of the Audit Committee, it is with great pleasure that I welcome Chris [...]

June 2nd, 2020|Press Release|

Virpax Pharmaceuticals Reports Pre-IND Guidance From FDA for DSF100

505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase 1 Human Study Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, received a written response from the US Food and [...]

September 12th, 2018|Press Release|

Virpax Pharmaceuticals Licenses Liposome Drug Delivery Technology From LipoCure

Virpax to Develop a Long-Acting Liposomal Gel (Lipogel) for Post-Operative Pain Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with LipoCure to develop pain management products using its liposome drug delivery technology. [...]

June 4th, 2018|Press Release|

Virpax Pharmaceuticals Licenses ‘Patch-in-a-Can’ MedSpray® Technology From MedPharm Ltd

Transdermal Delivery Technology Integrated Into DSF100 NSAID Spray Film 1.3% Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with MedPharm Ltd, a leading contract provider of topical and transdermal product design and [...]

May 29th, 2018|Press Release|
Go to Top